Additionally, in addition to HER2 amplification, somatic activating mutations within HER2 itself have recently been identified as drivers of tumorigenesis and had been observed first in non-small-cell lung cancer and then subsequently in a wide variety of cancers [76,77,78,79,80,81,82]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.